Neonatal Azithromycin Exposure and Childhood Growth: Long-Term Follow-Up of a Randomized Controlled Trial.

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH American Journal of Tropical Medicine and Hygiene Pub Date : 2024-07-16 Print Date: 2024-09-04 DOI:10.4269/ajtmh.24-0016

Mamadou Bountogo, Lucienne Ouermi, Clarisse Dah, Ali Sié, Boubacar Coulibaly, Alphonse Zakane, Thierry Ouedraogo, Mamadou Ouattara, Elodie Lebas, Ian Fetterman, Aimée Kimfuema, Thuy Doan, Thomas M Lietman, Catherine E Oldenburg

{"title":"Neonatal Azithromycin Exposure and Childhood Growth: Long-Term Follow-Up of a Randomized Controlled Trial.","authors":"Mamadou Bountogo, Lucienne Ouermi, Clarisse Dah, Ali Sié, Boubacar Coulibaly, Alphonse Zakane, Thierry Ouedraogo, Mamadou Ouattara, Elodie Lebas, Ian Fetterman, Aimée Kimfuema, Thuy Doan, Thomas M Lietman, Catherine E Oldenburg","doi":"10.4269/ajtmh.24-0016","DOIUrl":null,"url":null,"abstract":"<p><p>Single-dose azithromycin is being considered by the WHO as an intervention for prevention of child mortality. However, concerns have emerged related to longer term unintended consequences of early life antibiotic use, particularly among infants. We conducted a long-term follow-up in a random sample of children who had been enrolled in a trial of neonatal azithromycin versus placebo for prevention of mortality to assess whether neonatal azithromycin exposure led to differences in child growth up to 4 years of age. We found no evidence of a difference in any anthropometric outcome among children who had received a single oral dose of azithromycin compared with placebo during the neonatal period. These results do not support long-term growth-promoting or deleterious effects of early life azithromycin exposure.</p>","PeriodicalId":7752,"journal":{"name":"American Journal of Tropical Medicine and Hygiene","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376181/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Tropical Medicine and Hygiene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4269/ajtmh.24-0016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Single-dose azithromycin is being considered by the WHO as an intervention for prevention of child mortality. However, concerns have emerged related to longer term unintended consequences of early life antibiotic use, particularly among infants. We conducted a long-term follow-up in a random sample of children who had been enrolled in a trial of neonatal azithromycin versus placebo for prevention of mortality to assess whether neonatal azithromycin exposure led to differences in child growth up to 4 years of age. We found no evidence of a difference in any anthropometric outcome among children who had received a single oral dose of azithromycin compared with placebo during the neonatal period. These results do not support long-term growth-promoting or deleterious effects of early life azithromycin exposure.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新生儿阿奇霉素暴露与儿童成长：一项随机对照试验的长期随访。

世界卫生组织正在考虑将单剂量阿奇霉素作为预防儿童死亡的干预措施。然而，人们开始担心早期使用抗生素会带来长期的意外后果，尤其是在婴儿中。我们对参加新生儿阿奇霉素与安慰剂预防死亡试验的儿童进行了长期随机抽样随访，以评估新生儿阿奇霉素是否会导致儿童在 4 岁前的生长发育出现差异。我们发现，没有证据表明在新生儿期口服单剂量阿奇霉素的儿童与口服安慰剂的儿童在任何人体测量结果上存在差异。这些结果并不支持生命早期接触阿奇霉素会对生长产生长期的促进或有害影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American Journal of Tropical Medicine and Hygiene 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.20

自引率

3.00%

发文量

508

审稿时长

3 months

期刊介绍： The American Journal of Tropical Medicine and Hygiene, established in 1921, is published monthly by the American Society of Tropical Medicine and Hygiene. It is among the top-ranked tropical medicine journals in the world publishing original scientific articles and the latest science covering new research with an emphasis on population, clinical and laboratory science and the application of technology in the fields of tropical medicine, parasitology, immunology, infectious diseases, epidemiology, basic and molecular biology, virology and international medicine. The Journal publishes unsolicited peer-reviewed manuscripts, review articles, short reports, images in Clinical Tropical Medicine, case studies, reports on the efficacy of new drugs and methods of treatment, prevention and control methodologies,new testing methods and equipment, book reports and Letters to the Editor. Topics range from applied epidemiology in such relevant areas as AIDS to the molecular biology of vaccine development. The Journal is of interest to epidemiologists, parasitologists, virologists, clinicians, entomologists and public health officials who are concerned with health issues of the tropics, developing nations and emerging infectious diseases. Major granting institutions including philanthropic and governmental institutions active in the public health field, and medical and scientific libraries throughout the world purchase the Journal. Two or more supplements to the Journal on topics of special interest are published annually. These supplements represent comprehensive and multidisciplinary discussions of issues of concern to tropical disease specialists and health issues of developing countries